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Abstract
Background: The fatty acid profile is associated with the risk and progression of several diseases, probably via
mechanisms including its influence on gene expression. We previously reported a correlation between ECHDC3
upregulation and the severity of acute coronary syndrome. Here, we assessed the relationship of serum fatty acid
profile and ECHDC3 expression with the extent of coronary lesion.
Methods: Fifty-nine individuals aged 30 to 74 years and undergoing elective cinecoronariography for the first time
were enrolled in the present study. The extent of coronary lesion was assessed by the Friesinger index and patients
were classified as without lesion (n = 18), low lesion (n = 17), intermediate lesion (n = 17) and major lesion (n = 7).
Serum biochemistry, fatty acid concentration, and ECHDC3 mRNA expression in blood were evaluated.
Results: Elevated serum levels of oleic acid and total monounsaturated fatty acids were observed in patients with
low and intermediate lesion, when compared to patients without lesion (p < 0.05). ECHDC3 mRNA expression was 1.
2 fold higher in patients with low lesion than in patients without lesion (p = 0.020), and 1.8 fold lower in patients
with major lesion patients than in patients with low lesion (p = 0.023).
Conclusion: Increased levels of monounsaturated fatty acids, especially oleic acid, and ECHDC3 upregulation in
patients with coronary artery lesion suggests that these are independent factors associated with the initial
progression of cardiovascular disease.
Keywords: Oleic acid, ECHDC3, Friesinger index, Monounsaturated fatty acids, Cardiovascular diseases
Abbreviations: CVD, Cardiovascular disease; DHA, Docosahexaenoic; DPA, Docosapentaenoic;
EPA, Eicosapentaenoic; FA, Fatty acid; MUFA, Monounsaturated fatty acid; n3, Omega-3; n6, Omega-6;
PUFA, Polyunsaturated fatty acid; SFA, Saturated fatty acid.
Background
Cardiovascular disease (CVD) is the leading cause of death
worldwide. The early diagnosis of CVD along with proper
assessment of cardiovascular risk is crucial for further re-
duction of health care costs and mortality rates. Know-
ledge of the CVD physiopathology seems to be the best
approach to achieve these goals. ‘Omics’ analysis can con-
tribute to this field by providing fundamental information
to better understand complex biological systems, such as
atherosclerosis [1], the primary origin of most common
cardiovascular disorders [2].
Particularly, transcriptomics is a relevant tool for the
identification of diagnostic/prognostic biomarkers for
CVD. In a microarray-based gene expression study per-
formed previously by our research team, we found that
ECHDC3 mRNA expression was significantly increased
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within 2 h after an acute coronary syndrome, suggesting
this gene could be a potential novel biomarker for the early
stage of an acute episode [3]. However, the function of
ECHDC3 or its involvement with cardiovascular diseases
is scarcely explored in the literature, which might be due
to its recent identification. ECHDC3 encodes enoyl-CoA
hydratase domain containing 3, a mitochondrial enzyme
that has a crotonase-like domain similar to enoyl-CoA
hydratase [4]. Furthermore, ECHDC3 is presumed to be
involved in β-oxidation, the most important and well-
known pathway for fatty acid (FA) oxidation [5–7].
The consumption of specific dietary FAs has been
shown to influence risk and progression of several chronic
diseases, such as CVD, possibly by altering gene expres-
sion [8, 9]. However, studies in this field have provided
ambiguous results, especially regarding the effects of
monounsaturated FAs (MUFAs) on risk for coronary heart
disease [10]. Since there is no study evaluating the rela-
tionship between FA levels and genes related to CVD de-
velopment and progression yet, we aimed to evaluate the
serum FA profile and ECHDC3 expression in patients
with varying extent of coronary lesion.
Methods
Study population
Fifty-nine male and female individuals aged between 30
to 74 years that were undergoing cinecoronariography to
investigate extent of coronary lesion were enrolled in the
present study. Exclusion criteria included diagnosis of car-
diomyopathy, heart valve disease, congenital diseases,
pericarditis, coronary revascularization, chronic kidney
disease, liver failure, endocrine disorder (except for dia-
betes mellitus), inflammatory diseases, malignant diseases,
blood disorders, autoimmune diseases and family history
of hypercholesterolemia. Patients were selected at the
Hemodynamics unit of Hospital Universitário Onofre
Lopes. This study was approved by the hospital’s Re-
search Ethics Committee under protocol number CAAE
0001.0.051.294-11. All participants signed an informed
consent form.
Blood samples and biochemical analysis
Peripheral blood samples were obtained from patients.
Fasting serum glucose, total cholesterol and fractions,
urea, creatinine K, uric acid, alanine and aspartate amino-
transaminases were measured using colorimetric and
colorimetric-enzymatic methods in BIO-2000 IL, a semi-
automatic biochemical analyzer (Bioplus, São Paulo,
Brazil). Values of LDL-cholesterol were calculated accord-
ing to the Friedewald formula [11].
Extent of coronary lesion
The extent of coronary lesion was assessed by the
Friesinger index [12, 13]. Each of the three main coronary
arteries (anterior descending, circumflex and right coron-
ary) was scored separately from zero to five. Subjects were
classified as without lesion when the Friesinger index was
equal to 0; low lesion, when it varied from 1 to 5; inter-
mediate lesion, 6–10; and major lesion, 11–15, as adapted
from Chagas et al. (2013) [14].
Gas chromatography
Total serum lipids were extracted using a mixture of
methanol and chloroform chromatographic solution (2:1,
vol/vol), and FAs were converted to FA methyl esters using
a modified sodium methoxide method [15]. Then the FA
profile was estimated using flame-ionization gas chroma-
tography on a device (CG-2010, SHIMADZU, Kyoto,
Japan) equipped with a DB-FFAP capillary column (15 m×
0.100 mm× 0.10 μm [J&W Scientific from Agilent Tech-
nologies, Folsom, CA, USA]). Individual peaks were quanti-
fied as the area under the peak and results expressed as
percentages of the total area of all FA peaks [16].
RNA extraction and RT-qPCR
Total RNA was extracted from blood samples previously
stored in RNAlater® Stabilization Solution (Life Technolo-
gies, Carlsbad, CA, USA), using an RiboPureTM – Blood kit
(Life Technologies). RNA integrity was assessed by 1 %
agarose gel electrophoresis with MOPS buffer, while its
quantity was measured using Qubit® 2.0 Fluorometer (Life
Technologies). cDNA synthesis was performed using a High
Capacity cDNA Reverse Transcription Kit (Applied Biosys-
tems, Foster City, CA, USA) in a MyCycler Thermal Cycler
(BIO-RAD, Philadelphia, PA, USA). RT-qPCR was per-
formed using ECHDC3 TaqMan Assay (Hs00226727_m1)
(Life Technologies). The reference gene was selected from a
normalization study of three endogenous candidate genes:
GAPDH (Hs.592355), ACTB (Hs.520640), and 18S rRNA
(Hs.626362). RT-qPCR reactions were carried out in
96-well plates using the 7500 Fast Real-time PCR Sys-
tem (Applied Biosystems). Relative expression of ECHDC3
was calculated using the 2-deltaCT method [17] with ACTB
as a reference gene.
Statistical analysis
Statistical analysis was performed using SPSS® 22.0 soft-
ware (SPSS, Chicago, IL, USA). Normal distribution was
evaluated using the Kolmogorov-Smirnov test. Continuous
variables with normal distribution are presented as mean
and standard deviation and were compared using ANOVA
followed by Student’s t-test. Variables with skewed distribu-
tions are presented as median and interquartile range and
were analyzed using the Kruskal-Wallis test followed by
Mann-Whitney’s test. Categorical variables were compared
by chi-square test. Spearman and Pearson correlations were
performed between all continuous variables. The level of
statistical significance was accepted as p < 0.05.
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Results
According to the Friesinger index, the patients were
classified into four groups: without lesion (n = 18), low
lesion (n = 17), intermediate lesion (n = 17), and major
lesion (n = 7). Demographic, anthropometric, clinical,
and biochemical data of these groups are shown in
Table 1. We did not find significant differences among
the groups regarding clinical and biochemical data.
FA serum concentrations of the different groups are
shown in Table 2. Patients with low and intermediate lesion
presented higher concentrations of oleic acid (p = 0.025 and
p = 0.034, respectively) compared to patients without lesion.
Similarly, MUFA levels were higher in patients with low
and intermediate lesion (p = 0.023 and p = 0.040, respect-
ively) than in patients without lesion. We did not observe
significant changes in other FAs among the groups.
Regarding mRNA relative expression (Fig. 1), ECHDC3
mRNA expression were 1.2-fold higher in patients with
low lesion than in patients without lesion (p = 0.020),
and 1.8-fold lower in patients with major lesion than in
patients with low lesion (p = 0.023).
Pearson analysis showed a positive correlation between
oleic acid with triglyceride levels (r = 0.397, p = 0.002),
MUFA (r = 0.974, p < 0.001), SCD16 (r = 0.352, p = 0.006)
and SCD18 (r = 0.751, p < 0.001). ECHDC3 gene expression
positively correlated with SFA (r = 0.259, p = 0.048) and
negatively correlated with SCD16 (r = −0.289, p = 0.027).
Discussion
In the present study, all patients under CVD risk were
classified according to the presence and extent of coronary
lesion. Higher levels of MUFA, mainly oleic acid, and
ECHDC3 upregulation were found in patients with low
coronary lesion when compared to those without coron-
ary lesion, however we did not find significant difference
between patients with major lesions and those without
coronary lesion. These findings suggest that both observed
high oleic acid levels and ECHDC3 upregulation may
Table 1 Demographic, anthropometric and clinical data of patients classified according to the extent of coronary lesion
Variables Total
(n = 59)
Without lesion
(n = 18)
Low lesion
(n = 17)
Intermediate lesion
(n = 17)
Major lesion
(n = 7)
p-value
Age, years 60.0 ± 9.0 55.0 ± 9.0 62.0 ± 9.0 63.0 ± 10 60.0 ± 7.0 0.080
Sex male, % 54.2 44.4 58.8 64.7 42.9 0.582
BMI, kg/m2 26.82 ± 5.65 27.86 ± 4.70 25.27 ± 8.52 26.92 ± 4.29 27.43 ± 1.13 0.630
Obesity, % 20.3 33.3 17.6 17.6 0 0.133
Dyslipidemia, % 91.5 77.8 100.0 94.1 100.0 0.080
Diabetes mellitus, % 30,5 33.3 23.5 35.3 28.6 0.884
Hypertension, % 79.7 77.8 76.5 82.4 85.7 0.944
Diastolic pressure, mmHg 84.0 ± 20.0 81.0 ± 8.0 80.0 ± 24.0 90.0 ± 18.0 90.0 ± 32.0 0.355
Systolic pressure, mmHg 143.0 ± 26.0 137.0 ± 24.0 139.0 ± 22.0 155.0 ± 32.0 141.0 ± 21.0 0.187
Alcoholism, % 18.6 27.8 17.6 5.9 28.6 0.350
Smoking, % 22.0 27.8 17.6 17.6 28.6 0.825
Physical activity, % 47.5 50.0 58.8 35.3 42.9 0.573
Biochemical Analyses
Glucose, mmol/l 5.16 (3.72–21.87) 4.75 (3.89–14.26) 4.88 (3.75–11.04) 5.55 (3.72–21.87) 5.94 (4.44–13.04) 0.443
Total cholesterol, mmol/l 4.61 (2.95–7.85) 4.36 (3.08–6.50) 4.51 (3.19–6.89) 5.05 (2.95–7.85) 4.61(3.65–7.02) 0.555
HDL-cholesterol, mmol/l 0.92 (0.41–1.45) 0.95 (0.57–1.45) 0.93 (0.54–1.30) 0.91 (0.41–1.32) 0.83 (0.62–1.40) 0.669
LDL-cholesterol, mmol/l 2.68 (1.21–5.74) 2.38(1.49–4.57) 2.63(1.21–5.00) 3.26 (1.21–5.74) 2.89 (1.93–5.27) 0.419
Triglycerides, mmol/l 1.62 (0.75–9.47) 1.63 (0.79–6.94) 2.25(0.86–6.96) 1.62(0.75–9.47) 1.45 (0.85–3.24) 0.612
ALT, μKat/l 0.43 (0.17–2.19) 0.38 (0.17–1.57) 0.43 (0.25–1.04) 0.33 (0.17–2.19) 0.60 (0.25–1.45) 0.723
AST, μKat/l 0.52 (0.25–1.57) 0.52 (0.25–1.49) 0.43 (0.25–0.95) 0.52 (0.25–1.57) 0.60 (0.25–1.57) 0.546
Ureia, mmol/l 5.85 (3.34–10.35) 5.93 (3.34–9.52) 5.68 (4.31–9.85) 5.93(3.37–10.35) 5.85 (4.84–6.35) 0.693
Creatinine, μmol/l 79.56 (17.68–141.44) 79.56 (53.04–141.44) 79.56(53.04–123.76) 88.40 (53.04–106.08) 70.72 (17.68–106.08) 0.323
Uric acid, mmol/l 0.29 (0.11–0.52) 0.27(0.16–0.52) 0.28 (0.11–0.43) 0.29 (0.11–0.43) 0.33 (0.14–0.37) 0.965
Data are presented as mean ± standard deviation for parametric samples and as median (interquartile range) for non-parametric samples. Categorical variables
were compared by Chi-square test. Parametric analysis was performed by ANOVA way. Non-parametric samples were performed by Kruskal-Wallis test. P-values < 0.05
were considered statistically significant in all statistical test. BMI body mass index, HDL-cholesterol high density lipoprotein, LDL-cholesterol low density lipoprotein, AST
aspartate aminotransferase, ALT alanine transaminase
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induce initial events of the atherosclerotic process. There is
a large number of growth factors, cytokines, regulatory mol-
ecules and different cell types that are involved in athero-
sclerosis development, each having a different function [18].
Furthermore, the mechanisms underlying atherosclerosis
differ throughout the stages of disease, and a factor that is
important to the initial stage might not be relevant in the
late stage, supporting our results.
Oleic acid is an abundant monounsaturated omega-9
fatty acid that affects different biological processes, and
Table 2 Serum fatty acid concentration according to the extent of coronary lesion
Fatty acids (%) Total (n = 59) Without lesion (n = 18) Low lesion (n = 17) Intermediate lesion (n = 17) Major lesion (n = 7) p-value
SFA 44.12 ± 3.85 44.70 ± 4.18 43.79 ± 4.46 43.93 ± 2.74 43.93 ± 4.40 0.904
Myristic (C14:0) 0.89 ± 0.30 0.94 ± 0.36 0.91 ± 0.26 0.87 ± 0.31 0.80 ± 0.19 0.756
Palmitic (C16:0) 30.83 ± 3.07 31.40 ± 2.95 30.61 ± 3.15 30.52 ± 2.80 30.63 ± 4.22 0.830
Stearic (C18:0) 12.40 ± 1.89 12.36 ± 2.15 12.27 ± 2.10 12.54 ± 1.70 12.50 ± 1.30 0.979
MUFA 24.87 ± 3.10 23.66 ± 2.88 25.97 ± 2.84a 25.77 ± 2.96b 23.14 ± 3.35 0.032
Palmitoleic (C16:1) 2.55 ± 0.75 2.41 ± 0.62 2.73 ± .63 2.56 ± 0.89 2.47 ± 0.98 0.658
Oleic (C18:1) 22.32 ± 2.77 21.25 ± 2.54 23.24 ± 2.48c 23.22 ± 2.73d 20.66 ± 2.89 0.027
PUFA 31.01 ± 4.78 31.65 ± 4.46 30.24 ± 5.37 30.30 ± 3.99 32.94 ± 6.01 0.529
n-6 26.77 ± 4.29 27.26 ± 3.66 25.96 ± 5.13 26.46 ± 3.54 28.26 ± 5.53 0.628
Linoleic (C18:2) 18.06 ± 3.84 18.64 ± 3.29 17.23 ± 4.35 18.10 ± 3.30 18.47 ± 5.39 0.742
Arachidonic (C20:4) 8.71 ± 2.37 8.62 ± 1.73 8.73 ± 2.47 8.36 ± 2.20 9.78 ± 3.89 0.620
n-3 4.23 ± 1.17 4.38 ± 1.56 4.29 ± 1.02 3.84 ± 0.86 4.68 ± 0.91 0.363
a-linolenic (C18:3) 0.54 ± 0.20 0.56 ± 0.20 0.53 ± 0.21 0.52 ± 0.16 0.57 ± 0.31 0.916
EPA (C20:5) 0.46 ± 0.18 0.53 ± 0.24 0.42 ± 0.15 0.43 ± 0.16 0.52 ± 0.11 0.223
DPA (C22:5) 0.83 ± 0.23 0.83 ± 0.21 0.86 ± 0.17 0.80 ± 0.28 0.85 ± 0.33 0.891
DHA (C22:6) 2.39 ± 0.93 2.46 ± 1.26 2.48 ± 0.82 2.10 ± 0.67 2.74 ± 0.73 0.410
n-6/n-3 6.77 ± 2.12 6.80 ± 1.93 6.61 ± 2.96 7.14 ± 1.63 6.16 ± 1.29 0.765
SCD16 0.08 ± 0.02 0.08 ± 0.02 0.09 ± 0.02 0.08 ± 0.02 0.08 ± 0.03 0.398
SCD18 1.85 ± 0.40 1.77 ± 0.38 1.95 ± 0.38 1.90 ± 0.45 1.68 ± 0.36 0.376
Data are presented as mean ± standard deviation. Comparisons were performed by ANOVA way test followed by test t between pairs. P-values < 0.05 were
considered statistically significant for all statistical test
EPA, eicosapentaenoic, DHA docosahexaenoic, DPA docosapentaenoic SFA saturated fatty acid, MUFA monounsaturated fatty acid, PUFA polyunsaturated fatty acid,
n6 omega-6, n3 omega-3, SCD16 stearoyl-CoA-Desaturase 16, SCD18, stearoyl-CoA-Desaturase 18
ap = 0.023 for comparison between low lesion vs. without lesion groups by test t
bp = 0.040 for comparison between intermediate lesion vs. without lesion groups by test t
cp = 0.025 comparison between low lesion vs. without lesion groups by test t
dp = 0.034 for comparison between intermediate lesion vs. without lesion groups by test t
Fig. 1 ECHDC3 mRNA expression relative to ACTB expression according to the extent of coronary lesion. Data are presented as median and interquartile
range. Relative expression of ECHDC3 was calculated using the 2-deltaCT method. Statically analysis was performed by Kruskal-Wallis test followed by
Mann Whitney test
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is associated with increased expression of genes linked
to FA oxidation [19]. These genes are reported to be al-
tered during specific disease conditions that impact the
heart, including cardiac failure, myocardial ischemia, and
diabetes [20]. In the present study, a positive correlation
between oleic acid and triglycerides levels was observed
in patients with cardiac lesion, suggesting that there is a
potential influence of this FA on the increase of CVD
risk. This is supported by a study performed in healthy
individuals of both genders showing that virgin olive oil
consumption, a oleic acid-rich food, led to upregulation
of many genes associated with atherosclerosis disease
[21]. Moreover, in cultures of rat aortic smooth muscle
cells, the treatment with oleic acid was associated with
cell lipid accumulation, increasing foam cell formation
in a dose-dependent manner [22].
It was previously reported that ECHDC3 mRNA ex-
pression was significantly increased in patients with ST-
segment elevation myocardial infarction when compared
to unstable angina, indicating its association with the se-
verity of CVD [3]. The ECHDC3 role in CVD is scarcely
explored to allow a more comparative discussion of our
data, but is known that ECHDC2 upregulation in cardiac
tissue of rats was related to increased susceptibility to
myocardial ischemia/reperfusion injury [23]. ECHDC3
shares 30 % identity with ECHDC2 [24], and these pro-
teins may possibly have similar functions in the patho-
physiology of cardiovascular diseases. In addition, both
proteins are named after enoyl-CoA hydratase, an essen-
tial enzyme for the β-oxidation of FAs, because they
share a conserved domain [7, 23]. The potential involve-
ment of ECHDC3 in β-oxidation of FA pathway led us
to investigate the possible correlation between changes
of FA profile and this gene expression.
The high serum levels of oleic acid presently observed
might be due to stearoyl-CoA desaturase (SCD) activity, as
this fatty acid presented a positive correlation with SCD16
and SCD18 levels. Stearoyl-CoA desaturase (SCD) cata-
lyzes a rate-limiting step in the unsaturated FA synthesis,
which main product is oleic acid [25]. Notably, SCD has
been associated with inflammatory cluster [16] and meta-
bolic syndrome, reinforcing the impression of a detrimen-
tal association of oleic acid levels and CVD risk [26].
We do recognize some limitations of our study: the
diet of individuals was not studied, and the sample size
is small. However, to the best our knowledge, it is the
first study evaluating the relationship between ECHDC3
mRNA expression and FA levels in patients classified ac-
cording to the Friesinger index.
Conclusion
Our data suggests that increased oleic acid levels and
ECHDC3 upregulation in individuals with coronary ar-
tery lesion could be independent factors associated to
the early CVD development. More investigation is
needed to validate this hypothesis and to consider
whether the monitoring of FA serum levels, especially
the oleic acid, would be valuable for the assessment of
cardiovascular risk.
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